Risk factor
High price volatility
Profitability factor
Greatly overvalued vs peers
About
Nanjing Vazyme Biotech Co., Ltd., a biotechnology company, engages in the research, development, and production of enzymes, antigens, antibodies, and polymer organic materials. The company offers scientific research reagents, such as PCR clone point mutation, nucleic acid extraction, reverse transcription, qPCR, cell/protein, gene editing series, and instant granules; high-throughput sequencing library construction reagents, including DNA and RNA library, single cell epigenetic, magnetic, quantitative series, and cell-free DNA storage and extractions; and biomedical reagents and services. It serves scientific research institutions, high-throughput sequencing service companies, molecular diagnostic reagent manufacturers, pharmaceutical companies, CRO companies, hospitals, and other medical institutions. The company was founded in 2012 and is based in Nanjing, China.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued
Buy
Sell